Search Results for "Glaucoma Moringa Clinical Study"

16:09 EST 8th February 2016 | BioPortfolio

Matching Channels

Matching News

Transcend Medical Submits Final Module of FDA Premarket Approval Application for the CyPass(R) Glaucoma Micro-Stent

MENLO PARK, CA--(Marketwired - October 22, 2015) - Transcend Medical, Inc., a pioneer of minimally invasive glaucoma surgery (MIGS), today announced the submission to the U.S. Food and Drug Administra...

Envisia Therapeutics' Lead Product Candidate, ENV515 (travoprost XR), Achieves Primary Efficacy Endpoint In Phase 2a Glaucoma Clinical Trial

RESEARCH TRIANGLE PARK, N.C., Oct. 6, 2015 /PRNewswire/ -- Envisia Therapeutics, a clinical-stage biotechnology company focused on the development of novel extended-release therapi...

FDA Approves InnFocus Glaucoma Study Expansion

MIAMI, Nov. 10, 2015 /PRNewswire/ -- InnFocus Inc. announces it has received approval from the U.S. Food and Drug Administration (FDA) to expand to the pivotal final phase of its randomized clinical s...

Envisia Therapeutics Announces First Patient Dosed in Second Cohort of Novel Phase 2 Program Evaluating ENV515 in Patients with Glaucoma

RESEARCH TRIANGLE PARK, N.C., Jan. 12, 2016 /PRNewswire/ -- Envisia Therapeutics, a clinical-stage biotechnology company focused on the development of novel extended-release therapies in ophthalm...

Transcend Medical and Glaukos Corporation Settle Patent Litigation

MENLO PARK, CA--(Marketwired - October 30, 2015) - Transcend Medical, Inc. (“Transcend”) announced today that it has reached agreement with Glaukos Corporation (“Glaukos”) to settle the patent...

InnFocus MicroShunt® 3-Year Results of a Long Term Clinical Trial Show Long Lasting IOP Reduction

MIAMI, Jan. 27, 2016 /PRNewswire/ -- Glaucoma patients treated in a prospective clinical trial with the InnFocus MicroShunt® Drainage System and followed for over three years experienced sig...

InnFocus Closes $33.9 Million Series C Financing

MIAMI, Dec. 22, 2015 /PRNewswire/ -- InnFocus, Inc. reports it has closed its Series C financing, which raised additional monies to total $33.9 million. The Company is developing the InnFocus MicroShu...

InnFocus Concludes $32.8 Million Financing

MIAMI, Sept. 30, 2015 /PRNewswire/ -- InnFocus, Inc. reports the conclusion of a $32.8 million Series C financing. The Company is developing the InnFocus MicroShunt® glaucoma drainage system...

Matching PubMed Articles

Immunomodulatory activity of methanolic leaf extract of Moringa oleifera in Wistar albino rats.

Globally, Moringa oleifera is used by different communities to treat various ailments including modulation of the immune system though with limited scientific evidence.

Evaluation of the analgesic, anti-inflammatory, anti-oxidant, phytochemical and toxicological properties of the methanolic leaf extract of commercially processed Moringa oleifera in some laboratory animals.

Moringa oleifera Lam (Moringaceae) is a highly valued plant, distributed in many countries of the tropics and subtropics. It has an impressive range of medicinal uses with high nutritional value.

Antidiabetic activities of aqueous ethanol and n-butanol fraction of Moringa stenopetala leaves in streptozotocin-induced diabetic rats.

Moringa stenopetala has been used in traditional health systems to treat diabetes mellitus. The aim of this study was to investigate the antidiabetic activity of aqueous ethanol and n-butanol fraction...

Cultivation, Genetic, Ethnopharmacology, Phytochemistry and Pharmacology of Moringa oleifera Leaves: An Overview.

Moringa oleifera is an interesting plant for its use in bioactive compounds. In this manuscript, we review studies concerning the cultivation and production of moringa along with genetic diversity amo...

Occupational asthma to "the miracle tree" (Moringa oleifera): first description.

Search Whole site using Google

Quick Search
Advertisement Advertisement